https://www.selleckchem.com/pr....oducts/ITF2357(Givin
A traditional drug development paradigm was taken as the base case and financial impacts of the alternative development program were determined relative to the base case. Findings The total after-tax financial benefits of shorter development times from integrating formulation development, real-time manufacturing, and clinical testing when applied across a broad portfolio of investigational drugs ranged from $230.5 million to $290.1 million, $196.4 million to $247.5 million, and $102.6 million to $275.5 million, per approved
Curtir
Comentario
Compartilhar
